IMMX

Immix Biopharma Inc

• TipRanks·10/20 12:05

  Immix Biopharma price target raised to $20 from $19 at Morgan Stanley

• NASDAQ·10/02 16:13

  Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

• NASDAQ·10/02 11:46

  Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04

• TipRanks·09/30 21:29

  Immix Biopharma Prices $125 Million Equity Offering

• TipRanks·09/30 11:10

  Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Immix Biopharma (IMMX) and Surgery Partners (SGRY)

• Dow Jones·09/29 17:04

  Immix Biopharma Is Maintained at Buy by Needham

• Dow Jones·09/29 17:04

  Immix Biopharma Price Target Raised to $30.00/Share From $21.00 by Needham

• TipRanks·09/29 16:55

  Analyst Gil Blum Lifts Immix Biopharma Price Target to $30 on Strong NEXICART-2 Data and Accelerated Commercial Path

• TipRanks·09/29 16:01

  Midday Fly By: OpenAI scraps new AI model launch, Oura postpones IPO

• TipRanks·09/29 16:00

  Analysts’ Top Healthcare Picks: uniQure (QURE), Immix Biopharma (IMMX)

• TipRanks·09/29 15:45

  Immix Biopharma price target raised to $30 from $27 at BofA

• NASDAQ·09/29 13:48

  ImmixBio Reports 89% CR Rate, Potential 98% With NXC-201 In AL Amyloidosis

• NASDAQ·09/29 13:40

  Immix Biopharma's NXC-201 Shows 89% Complete Response Rate In AL Amyloidosis

• Seeking Alpha·09/29 13:13

  Immix rises after new mid-stage trial data for AL amyloidosis therapy

• Seeking Alpha·09/29 11:33

  Immix Biopharma prices $125M stock offering